NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Travere Therapeutics, Inc. (TVTX) Stock Analysis

Travere Therapeutics, Inc. (TVTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TVTX

$52.58

+$0.28 (+0.54%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TVTX with… →

TVTX Key Statistics

As of Oct 21, 2026
Trading
Open
$52.50
Previous Close
$52.30
Day's Range
52.50–54.83
52-Week Range
22.59–68.73
Volume
2.16M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.14
Valuation
Market Cap
$4.96B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.22
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.38
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.74
Financials (FY)
Revenue (FY)
$490.73M+110.45%
Net Income (FY)
−$25.55M
Profit marginThe share of revenue left as profit after all costs and taxes.
−7.35%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
94.26M
1-Year Return
+89.14%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
1.66M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TVTX closed at $52.58, +89.14% over 1 year.

Travere Therapeutics, Inc. (TVTX) has a market capitalization of $4.96B.

In fiscal 2025, TVTX reported revenue of $490.73M.

TVTX Stock Return by Calendar Year

Travere Therapeutics, Inc. (TVTX) 10-year return: what $10,000 became

1 year
$10,000 $18,914
+89.14%
5 years
$10,000 $20,840
+108.40%
10 years
$10,000 $25,549
+155.49%

If you had invested $10,000 in Travere Therapeutics, Inc. (TVTX) 10 years ago, at the close on October 21, 2016, it would have been worth $25,549 at the close on October 21, 2026: +155.49% in total, +9.83% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+37.61%
2025+119.35%
2024+93.77%
2023−57.25%
2022−32.25%
2021+13.89%
2020+91.94%
2019−37.25%
2018+7.40%
2017+11.30%
2016 (partial year)+1.45%

As of October 21, 2026.

TVTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$490.73M−$25.55M−5.2%
2024$233.18M−$321.55M−137.9%
2023$145.24M−$111.40M−76.7%
2022$109.46M−$278.48M−254.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$490.73M$480.39M−$62.82M−$25.55M−5.2%
2024$233.18M$225.43M−$321.39M−$321.55M−137.9%
2023$145.24M$133.79M−$376.74M−$111.40M−76.7%
2022$109.46M$105.04M−$319.81M−$278.48M−254.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TVTX Valuation vs Biotechnology Median

Median of 608 stocks
MetricTVTXBiotechnology medianvs median
P/S ratio8.3813.3037% below
Profit margin−7.35%−38.31%31.0 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Travere Therapeutics, Inc. (TVTX) is capitalised at $4.96B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 497.

TVTX last closed at $52.58 on October 21, 2026. That is +$0.28 (+0.54%) against the previous close. Over the past 52 weeks the price has ranged from $22.59 to $68.73. The latest close sits 132.76% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $490.73M. That is +110.45% against the prior fiscal year, when revenue was $233.18M. The same year closed with a net loss of $25.55M. The reported profit margin is −7.35%. That is 31 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.74.

Across the 4 fiscal years on file, revenue moves from $109.46M in 2022 to $490.73M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 9.22. Measured against sales, the shares trade at 8.38 times revenue. On price-to-sales that is 36.97% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.14. Annualized volatility over the trailing 10 years is 57.86%. Over the trailing twelve months the total return is +89.14%. Measured over 10 years, that is +9.83% a year compounded.

Growth & Income

No dividend is on file for TVTX.

So far in 2026 the total return is +37.61%. Across the complete calendar years on file, 2025 returned +119.35% and 2023 returned −57.25%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Travere Therapeutics, Inc. (TVTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Travere Therapeutics, Inc. TVTX $4.96B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Travere Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Visit website →